Summarized by Masters of Longevity from Peter Attia Blog.
Reports on clinical efforts to prevent Alzheimer’s by targeting early amyloid pathology and shifting treatment earlier in the disease process.
Key Takeaways
- Monoclonal antibodies that clear brain beta-amyloid have shown modest slowing of cognitive decline in Phase III trials.
- Therapeutic effects were limited likely because trials enrolled patients already showing mild cognitive impairment or early dementia.
- Companies are launching prevention trials aimed at intervening earlier in the amyloid cascade to prevent downstream tau and glial damage.
